Biogen (BIIB) Debt to Equity (2008 - 2026)
Biogen (BIIB) debt to equity from Dec 31, 2008 to Mar 31, 2026. The current Biogen (BIIB) debt to equity is 33.72%. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Debt to Equity
Debt to Equity
Annual Debt to Equity change of Biogen (BIIB)
| Year | Debt to Equity | Change |
|---|---|---|
| 2025 | 34.44% | -28.44% |
| 2024 | 48.12% | +0.48% |
| 2023 | 47.90% | +2.16% |
| 2022 | 46.88% | -29.77% |
| 2021 | 66.75% | -3.82% |
| 2020 | 69.40% | +55.51% |
| 2019 | 44.63% | -1.97% |
| 2018 | 45.53% | -3.30% |
| 2017 | 47.08% | -12.30% |
| 2016 | 53.68% | -22.90% |
| 2015 | 69.63% | +1190.08% |
| 2014 | 5.40% | -21.93% |
| 2013 | 6.91% | -57.81% |
| 2012 | 16.39% | +2.86% |
| 2011 | 15.93% | -16.95% |
| 2010 | 19.18% | N/A |
| 2009 | 0.00% | N/A |
| 2008 | 0.00% | N/A |
Comparison Biogen (BIIB) debt to equity with competitors
Biogen (BIIB) debt to equity is 33.72%.
| Ticker | Name | Debt to Equity | Upside |
|---|---|---|---|
| SNY | Sanofi | 27.50% | -18.44% |
| JNJ | Johnson & Johnson | 67.73% | +100.89% |
| PFE | Pfizer Inc | 71.50% | +112.08% |
| AZN | Astrazeneca plc | 71.66% | +112.54% |
| NVO | Novo Nordisk | 72.09% | +113.81% |
| GILD | Gilead Sciences Inc | 94.30% | +179.69% |
| GSK | GSK Plc | 106.74% | +216.60% |
| MRK | Merck & Co Inc | 107.06% | +217.54% |
| NVS | Novartis AG | 122.03% | +261.96% |
| LLY | Lilly(Eli) & Company | 139.02% | +312.32% |
| MDCX | MDCorp | 176.75% | +424.23% |
| MDCXW | Medicus Pharma Ltd warrant | 176.75% | +424.23% |
| GRFS | Grifols SA | 177.15% | +425.44% |
| BMY | Bristol-Myers Squibb Company | 219.95% | +552.38% |
| AMGN | AMGEN Inc | 623.75% | +1750.06% |
| OGN | Organon & Company | 948.95% | +2714.58% |